1. Home
  2. EDSA vs PCLA Comparison

EDSA vs PCLA Comparison

Compare EDSA & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • PCLA
  • Stock Information
  • Founded
  • EDSA 2015
  • PCLA 2008
  • Country
  • EDSA Canada
  • PCLA Japan
  • Employees
  • EDSA N/A
  • PCLA N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • EDSA Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • EDSA Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • EDSA 17.2M
  • PCLA 18.6M
  • IPO Year
  • EDSA N/A
  • PCLA 2025
  • Fundamental
  • Price
  • EDSA $2.39
  • PCLA $0.50
  • Analyst Decision
  • EDSA Strong Buy
  • PCLA
  • Analyst Count
  • EDSA 2
  • PCLA 0
  • Target Price
  • EDSA $13.00
  • PCLA N/A
  • AVG Volume (30 Days)
  • EDSA 11.7K
  • PCLA 199.5K
  • Earning Date
  • EDSA 08-08-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • EDSA N/A
  • PCLA N/A
  • EPS Growth
  • EDSA N/A
  • PCLA N/A
  • EPS
  • EDSA N/A
  • PCLA N/A
  • Revenue
  • EDSA N/A
  • PCLA $5,475,228.00
  • Revenue This Year
  • EDSA N/A
  • PCLA N/A
  • Revenue Next Year
  • EDSA N/A
  • PCLA N/A
  • P/E Ratio
  • EDSA N/A
  • PCLA N/A
  • Revenue Growth
  • EDSA N/A
  • PCLA 40.19
  • 52 Week Low
  • EDSA $1.55
  • PCLA $0.37
  • 52 Week High
  • EDSA $5.00
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 51.55
  • PCLA 46.55
  • Support Level
  • EDSA $2.41
  • PCLA $0.42
  • Resistance Level
  • EDSA $2.47
  • PCLA $0.55
  • Average True Range (ATR)
  • EDSA 0.09
  • PCLA 0.04
  • MACD
  • EDSA -0.01
  • PCLA 0.02
  • Stochastic Oscillator
  • EDSA 48.15
  • PCLA 63.36

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: